Abstract
Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 218-220 |
| Number of pages | 3 |
| Journal | Journal of the American Medical Association |
| Volume | 238 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 18 1977 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Purified Duck Embryo Rabies Vaccine : An Accelerated Schedule for Preexposure Immunization Against Rabies. / Nelson, Kenrad Edwin; Batt, Murray D.; Vithayasai, Vicharn; Makornkawkayoon, Sanit; Panas-Amporn, Kampol; Anderson, John T.
In: Journal of the American Medical Association, Vol. 238, No. 3, 18.07.1977, p. 218-220.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Purified Duck Embryo Rabies Vaccine
T2 - An Accelerated Schedule for Preexposure Immunization Against Rabies
AU - Nelson, Kenrad Edwin
AU - Batt, Murray D.
AU - Vithayasai, Vicharn
AU - Makornkawkayoon, Sanit
AU - Panas-Amporn, Kampol
AU - Anderson, John T.
PY - 1977/7/18
Y1 - 1977/7/18
N2 - Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).
AB - Seroconversion and adverse reaction rates were studied in 92 persons given four or five doses in a two-week period of duck embryo rabies vaccine (DEV) or duck embryo rabies vaccine purified by ultracentrifugation (P-DEV). Mouse-neutralizing antibodies developed in 78 of 92 (84.8%) persons in these accelerated schedules. There were no significant differences in the frequency of antibody conversion or in geometric mean titers of antibody between persons given either vaccine. However, local and systemic adverse reactions were substantially less common with P-DEV. These data suggest that four or five doses of DEV or P-DEV given in a two-week course can be used for preexposure prophylaxis in situations where the more drawn-out regimens would result in continuation of a high-risk of rabies exposure. The antibody response of persons given this more accelerated regimen must be determined. (JAMA 238:218-220, 1977).
UR - http://www.scopus.com/inward/record.url?scp=84944967429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944967429&partnerID=8YFLogxK
U2 - 10.1001/jama.1977.03280030026014
DO - 10.1001/jama.1977.03280030026014
M3 - Article
C2 - 577520
AN - SCOPUS:84944967429
VL - 238
SP - 218
EP - 220
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0098-7484
IS - 3
ER -